The challenges of clinical trials for adolescents and young adults with cancer
The challenges of clinical trials for adolescents and young adults with cancer
复制标题
DOI：
10.1002/pbc.21459
复制
发表时间：
2008-05-01
影响因子：
3.2
通讯作者：
Bleyer, Archie
中科院分区：
文献类型：
--
作者：
Ferrari, Andrea;Montello, Michael;Bleyer, Archie
在美国、欧洲和澳大利亚，可能还有世界上所有国家，患有癌症的老年青少年和年轻人在可以改善其结果的治疗临床试验中所占比例不足。同时，这些患者的生存率和死亡率反映了临床试验的累积模式，与年轻和老年患者相比几乎没有改善。这表明，青少年和年轻患者参与临床试验的相对缺乏，降低了他们获得与其他年龄组患者一样好的结果的机会。因此，如果要消除目前年轻人和老年青少年的结果缺陷，增加临床试验的可用性和参与度至关重要。无论是否存在因果关系，临床试验活动量低对我们在青春期和成年早期进一步了解癌症的科学知识和管理的影响都是有害的。
In the United States, Europe, and Australia, and probably all countries of the world, older adolescents and young adults with cancer are under-represented in clinical trials of therapies that could improve their outcome. Simultaneously, the survival and mortality rates in these patients have mirrored the clinical trial accrual pattern, with little improvement compared with younger and older patients. This suggests that the relative lack of participation of adolescent and young adult patients in clinical trials has lessened their chances for as good an outcome as that enjoyed by patients in other age groups. Thus, increased availability of and participation in clinical trials is of paramount important if the current deficits in outcome in young adults and older adolescents are to be eliminated. Regardless of whether there is a causal relationship, the impact of low clinical trial activity on furthering our scientific knowledge and management of cancer during adolescence and early adulthood is detrimental.